Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia

被引:40
作者
Hochhaus, A
Yan, XH
Willer, A
Hehlmann, R
Gordon, MY
Goldman, JM
Melo, JV
机构
[1] ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LRF CTR ADULT LEUKAEMIA,LONDON W12 0HS,ENGLAND
[2] UNIV HEIDELBERG,KLINIKUM MANNHEIM,MED KLIN 3,D-6800 MANNHEIM,GERMANY
关键词
interferon regulatory factors; interferon-alpha; chronic myeloid leukaemia;
D O I
10.1038/sj.leu.2400723
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interferon regulatory factors (IRF) 1 and 2 are DNA-binding proteins which control interferon (IFN) gene expression. IRF1 functions as an activator for IFN and IFN-inducible genes, whereas IRF2 represses the action of IRF1. Expression of the two regulatory genes is itself IFN-inducible. Because therapeutic responses of chronic myeloid leukaemia (CML) patients to IFN-alpha may be determined by intracellular levels of these two mutually antagonistic transcription factors, we have devised a competitive reverse-transcription polymerase chain reaction (RT-PCR) assay which provides an estimate of the ratio of IRF1 to IRF2 expression in a given cell population. Analysis of peripheral blood leucocytes from 25 normal individuals showed that the IRF1:IRF2 ratio varied between 1.13 and 2.30 (mean +/- s.d. 1.49 +/- 0.33). Similar values were obtained for normal bone marrow specimens, with no significant difference between CD34(+) and CD34(-) cells. In contrast, the IRF1:IRF2 ratio in leucocytes from CML patients showed a much wider variation (0.53-5.11). Eleven out of 130 patients in chronic phase had ratios above the normal range, whereas none of the 33 blast crisis samples had a ratio >2.5. Analysis of diagnostic specimens in 59 CML patients treated subsequently with IFN-alpha showed a high IRF1:IRF2 ratio of 5.11 in one of two patients who became complete responders; all the 53 patients with minimal or no cytogenetic response had ratios below 2.5. In a separate series of 97 CML patients studied after IFN-alpha therapy a highly significant correlation was found between the IRF1:IRF2 ratio and both the cytogenetic and the molecular response tie low concentration of BCR-ABL transcripts) to treatment: 53 out of 115 prospectively analysed samples of good cytogenetic responders had ratios above 2.0, as opposed to only 13 out of 91 samples from poor responders (P < 0.0001; chi(2) test). We conclude that a high ratio of IRF1/IRF2 expression may be associated with good cytogenetic and molecular response to IFN-alpha in CML.
引用
收藏
页码:933 / 939
页数:7
相关论文
共 24 条
[1]  
ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401
[2]  
CHA Y, 1994, J BIOL CHEM, V269, P5279
[3]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[4]  
CROSS NCP, 1994, LEUKEMIA, V8, P186
[5]  
CROSS NCP, 1996, METH MOLEC MED, P25
[6]  
DOWDING C, 1991, BLOOD, V78, P499
[7]   Induction of interferon regulatory factors, 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness [J].
Fischer, T ;
Aman, J ;
vanderKuip, H ;
Rudolf, G ;
Peschel, C ;
Aulitzky, WE ;
Huber, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (03) :595-603
[8]   MECHANISM OF ACTION OF ALPHA-INTERFERON IN CHRONIC GRANULOCYTIC-LEUKEMIA - EVIDENCE FOR PREFERENTIAL INHIBITION OF LATE PROGENITORS [J].
GALVANI, DW ;
CAWLEY, JC .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (04) :475-479
[9]   ANTI-ONCOGENIC AND ONCOGENIC POTENTIALS OF INTERFERON REGULATORY FACTOR-I AND FACTOR-II [J].
HARADA, H ;
KITAGAWA, M ;
TANAKA, N ;
YAMAMOTO, H ;
HARADA, K ;
ISHIHARA, M ;
TANIGUCHI, T .
SCIENCE, 1993, 259 (5097) :971-974
[10]   STRUCTURALLY SIMILAR BUT FUNCTIONALLY DISTINCT FACTORS, IRF-1 AND IRF-2, BIND TO THE SAME REGULATORY ELEMENTS OF IFN AND IFN-INDUCIBLE GENES [J].
HARADA, H ;
FUJITA, T ;
MIYAMOTO, M ;
KIMURA, Y ;
MARUYAMA, M ;
FURIA, A ;
MIYATA, T ;
TANIGUCHI, T .
CELL, 1989, 58 (04) :729-739